Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
85,500
+400 (0.47%)
Last updated: Jun 5, 2025
KRX:185750 Revenue
Chong Kun Dang Pharmaceutical had revenue of 400.96B KRW in the quarter ending March 31, 2025, with 10.91% growth. This brings the company's revenue in the last twelve months to 1.63T, down -2.39% year-over-year. In the year 2024, Chong Kun Dang Pharmaceutical had annual revenue of 1.59T, down -4.97%.
Revenue (ttm)
1,625.88B
Revenue Growth
-2.39%
P/S Ratio
0.69
Revenue / Employee
714.36M
Employees
2,276
Market Cap
1,126.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,586.43B | -82.97B | -4.97% |
Dec 31, 2023 | 1,669.40B | 181.06B | 12.17% |
Dec 31, 2022 | 1,488.34B | 144.79B | 10.78% |
Dec 31, 2021 | 1,343.56B | 40.55B | 3.11% |
Dec 31, 2020 | 1,303.01B | 223.67B | 20.72% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
PharmaResearch | 392.31B |
LigaChem Biosciences | 146.42B |